June 21 (Reuters) - Leap Therapeutics Inc
* Leap therapeutics announces collaboration with merck to evaluate keytruda® (pembrolizumab) in combination with dkn-01 in esophagogastric cancer
* Leap therapeutics inc - additional details of collaboration were not disclosed.
* Leap therapeutics inc - collaboration agreement is between leap and merck, through a subsidiary
* Leap therapeutics inc - study is expected to begin enrolling patients in second-half of 2017 Source text for Eikon: Further company coverage: